Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Adam S. Cheifetz, María T. Abreu, Waqqas Afif, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 10, pp. 2014-2025
Open Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Peter M. Irving, K Gecse
Gastroenterology (2022) Vol. 162, Iss. 5, pp. 1512-1524
Open Access | Times Cited: 73
Study of tumor necrosis factor receptor in the inflammatory bowel disease
Roberta Figueiroa Souza, Marcos Antônio Ferreira Caetano, Henrique Inhauser Riceti Magalhães, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 18, pp. 2733-2746
Open Access | Times Cited: 48
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
Neil Chanchlani, Simeng Lin, Claire Bewshea, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 6, pp. 521-538
Open Access | Times Cited: 33
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial
Nisha R. Acharya, Athimalaipet V Ramanan, Alison B Coyne, et al.
The Lancet (2025) Vol. 405, Iss. 10475, pp. 303-313
Open Access | Times Cited: 1
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro–de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 46
Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Nghia Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 937-949.e2
Open Access | Times Cited: 45
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
Fabio Salvatore Macaluso, Claudio Papi, Ambrogio Orlando, et al.
Digestive and Liver Disease (2023) Vol. 55, Iss. 4, pp. 442-453
Open Access | Times Cited: 23
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Matthew C. Choy, C Li Wai Suen, Danny Con, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 11, pp. 981-996
Closed Access | Times Cited: 13
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
Fabio Salvatore Macaluso, Ambrogio Orlando, Claudio Papi, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 4, pp. 440-451
Open Access | Times Cited: 33
Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology
Xinyu Liu, Hao Tang, Qingyang Zhou, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 2, pp. 272-285
Open Access | Times Cited: 19
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Namita Singh, Marla C. Dubinsky
Springer eBooks (2023), pp. 445-456
Closed Access | Times Cited: 16
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease
Abhinav Vasudevan, Vivek Tharayil, Laura H. Raffals, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 4, pp. 660-670
Open Access | Times Cited: 15
Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease
Casper Steenholdt, Ruben Due Lorentsen, Pernille Nørgaard Petersen, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 6, pp. 1088-1098
Closed Access | Times Cited: 6
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”
Patricia Ortiz-Fernández, Carles Iniesta Navalón, Elena Urbieta-Sanz, et al.
Clinical Rheumatology (2025)
Open Access
Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize TNF-alpha inhibitor treatment for uveitis
H Chen, Jenny Shunyakova, Amit K. Reddy, et al.
Frontiers in Ophthalmology (2025) Vol. 5
Open Access
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Andrés Yarur, Thierry Dervieux, Ryan C. Ungaro, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 187-187
Open Access
Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
The role of immunogenicity in optimizing biological therapies for inflammatory bowel disease
Konika Sharma, Brad W. deSilva, Stephen B. Hanauer
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules
Huibo Li, Jia Wang, Yang Hu, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 312-312
Open Access
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Suivi immunologique des biothérapies
Carole Emile
Option/Bio (2025) Vol. 36, Iss. 701-702, pp. 24-27
Closed Access
Page 1 - Next Page

Scroll to top